NASDAQ:IONS Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis $51.45 -0.41 (-0.79%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$51.05▼$52.3450-Day Range$36.45▼$51.8652-Week Range$35.95▼$54.44Volume766,354 shsAverage Volume1.39 million shsMarket Capitalization$7.51 billionP/E RatioN/ADividend YieldN/APrice Target$60.18 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ionis Pharmaceuticals alerts: Email Address Ionis Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.79 Rating ScoreUpside/Downside17.0% Upside$60.18 Price TargetShort InterestBearish6.98% of Float Sold ShortDividend StrengthN/ASustainability-3.58Upright™ Environmental ScoreNews Sentiment0.69Based on 32 Articles This WeekInsider TradingSelling Shares$856,260 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.96) to ($3.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.90 out of 5 starsMedical Sector225th out of 936 stocksPharmaceutical Preparations Industry98th out of 436 stocks 3.4 Analyst's Opinion Consensus RatingIonis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 12 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageIonis Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ionis Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.98% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Ionis Pharmaceuticals has recently decreased by 1.58%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIonis Pharmaceuticals has received a 27.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication" product. See details.Environmental SustainabilityThe Environmental Impact score for Ionis Pharmaceuticals is -3.58. Previous Next 2.6 News and Social Media Coverage News SentimentIonis Pharmaceuticals has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 32 news articles for Ionis Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 10 people have searched for IONS on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.MarketBeat Follows6 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $856,260.00 in company stock.Percentage Held by InsidersOnly 2.71% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ionis Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($3.96) to ($3.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -19.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -19.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 19.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ionis Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Ionis Pharmaceuticals Stock (NASDAQ:IONS)Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Read More IONS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IONS Stock News HeadlinesJuly 18, 2024 | insidertrades.comJoseph Klein III Sells 12,000 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockJuly 27 at 1:40 AM | americanbankingnews.comQ2 2024 Earnings Forecast for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Issued By Leerink PartnrsJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 26 at 1:53 AM | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Upgraded to Strong-Buy at Leerink PartnrsJuly 25 at 1:00 PM | msn.comLeerink Partners Upgrades Ionis Pharmaceuticals (IONS)July 24 at 12:49 PM | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $59.00July 24 at 12:03 PM | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Price Target Increased to $68.00 by Analysts at Bank of AmericaJuly 24 at 8:58 AM | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Upgraded to "Outperform" by SVB LeerinkJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 24 at 8:08 AM | marketwatch.comIonis Shares Rise 6% After Results Angelman Syndrome Treatment DataJuly 24 at 8:08 AM | markets.businessinsider.comIonis Pharmaceuticals’ ION582 Garners Buy Rating Amidst Promising Efficacy and Safety DataJuly 24 at 2:44 AM | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Rating Reiterated by Needham & Company LLCJuly 23, 2024 | finanznachrichten.deIonis Pharmaceuticals, Inc.: Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndromeJuly 23, 2024 | seekingalpha.comIonis Pharmaceuticals, Inc. (IONS) HALOS Study of ION582 in Angelman Syndrome - (Transcript)July 22, 2024 | benzinga.comIonis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: AnalystJuly 22, 2024 | investors.comIonis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen WrongJuly 22, 2024 | markets.businessinsider.comIonis Pharma Announces Positive Results From Phase 1/2 Study Of ION582 In Angelman SyndromeJuly 22, 2024 | prnewswire.comIonis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndromeSee More Headlines Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:IONS CUSIP46433010 CIK874015 Webwww.ionispharma.com Phone(760) 931-9200Fax760-603-2700Employees927Year FoundedN/APrice Target and Rating Average Stock Price Target$60.18 High Stock Price Target$82.00 Low Stock Price Target$28.00 Potential Upside/Downside+17.0%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)($2.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-366,290,000.00 Net Margins-49.49% Pretax Margin-46.88% Return on Equity-107.64% Return on Assets-13.17% Debt Debt-to-Equity Ratio4.15 Current Ratio7.37 Quick Ratio7.28 Sales & Book Value Annual Sales$788 million Price / Sales9.53 Cash FlowN/A Price / Cash FlowN/A Book Value$2.70 per share Price / Book19.06Miscellaneous Outstanding Shares145,960,000Free Float142,009,000Market Cap$7.51 billion OptionableOptionable Beta0.40 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Brett P. Monia Ph.D. (Age 63)Founder, CEO & Director Comp: $2.38MMs. Elizabeth L. Hougen M.A. (Age 62)M.B.A., M.S., Executive VP of Finance & CFO Comp: $1.14MMs. B. Lynne Parshall Esq. (Age 70)J.D., Director Comp: $90kDr. Richard S. Geary Ph.D. (Age 66)Executive VP & Chief Development Officer Comp: $1.01MDr. Eric E. Swayze Ph.D. (Age 58)Executive Vice President of Research Comp: $1.01MMr. Darren GonzalesChief Accounting Officer & Senior VPDr. C. Frank Bennett BSc (Age 67)Ph.D., Executive VP & Chief Scientific Officer Comp: $651.64kMr. D. Wade Walke Ph.D.Senior Vice President of Investor RelationsMr. Patrick R. O'Neil Esq. (Age 50)Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary Comp: $815.69kMs. Hayley SofferVice President of Corporate CommunicationsMore ExecutivesKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZPerrigoNYSE:PRGOUltragenyx PharmaceuticalNASDAQ:RAREBiohavenNYSE:BHVNArrowhead PharmaceuticalsNASDAQ:ARWRView All CompetitorsInsiders & InstitutionsARK Investment Management LLCSold 38,827 shares on 7/26/2024Ownership: 0.932%BLB&B Advisors LLCBought 7,650 shares on 7/26/2024Ownership: 0.105%Liontrust Investment Partners LLPSold 228,900 shares on 7/26/2024Ownership: 0.041%Checchi Capital Advisers LLCBought 4,234 shares on 7/26/2024Ownership: 0.003%Baillie Gifford & Co.Sold 35,429 shares on 7/25/2024Ownership: 0.178%View All Insider TransactionsView All Institutional Transactions IONS Stock Analysis - Frequently Asked Questions How have IONS shares performed this year? Ionis Pharmaceuticals' stock was trading at $50.59 on January 1st, 2024. Since then, IONS shares have increased by 1.7% and is now trading at $51.45. View the best growth stocks for 2024 here. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its earnings results on Tuesday, May, 7th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.12. Ionis Pharmaceuticals's revenue for the quarter was down 9.2% compared to the same quarter last year. Who are Ionis Pharmaceuticals' major shareholders? Top institutional shareholders of Ionis Pharmaceuticals include ARK Investment Management LLC (0.93%), Baillie Gifford & Co. (0.18%), Sumitomo Mitsui Trust Holdings Inc. (0.14%) and BLB&B Advisors LLC (0.11%). Insiders that own company stock include Brett P Monia, Elizabeth L Hougen, B Lynne Parshall, C Frank Bennett, Patrick R O'neil, Eugene Schneider, Brian Birchler, Eric Swayze, Onaiza Cadoret-Manier, Joseph Baroldi, Joseph Klein III and Allene M Diaz. View institutional ownership trends. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ionis Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY) and Biogen (BIIB). This page (NASDAQ:IONS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.